Skip to content

Corvus Pharmaceuticals CRVS Ratios & Valuation

FY'25FY'24FY'23FY'22
Returns
Return on equity-32.6%+142pp-174.9%-118pp-57%-3.1pp-53.9%-2.8pp
Return on assets-21.8%+87.0pp-108.8%-61.3pp-47.5%-1.0pp-46.5%-2.1pp
Return on invested capital-104.2%+1.0pp-105.2%-41.0pp-64.1%+14.4pp-78.6%+2.5pp
Liquidity
Current ratio6.2×+4.7×1.5×-2.5×4.1×0.0×4.1×-3.3×
Quick ratio6.2×+4.7×1.5×-2.5×4.1×0.0×4.1×-3.3×
Cash ratio0.5×+0.2×0.2×-1.6×1.8×+0.6×1.2×-5.3×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Per Share
Book value per share$0.77+43.7%$0.53-33.7%$0.81-33.2%$1.21-48.1%
Valuation
Market capitalization$1.1B+259%$343.78M+298%$86.31M+118%$39.57M-64.7%
Enterprise value$1.06B+251%$336.16M+348%$75.06M+159%$29.01M-44.6%
Price / book4.6×-1.6×10.6×+8.3×2.2×+1.5×0.7×-0.4×
Free cash flow yield-3.2%-27.8%
Earnings yield-4%+9.5pp-18.1%+13.2pp-31.3%+73.1pp-104.4%-65.8pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Corvus Pharmaceuticals's ratios come from?
Every ratio is computed from Corvus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.